Kelly E. McCann, MD, PhD

Panelists discuss how emerging developments in HER2-positive (HER2+) breast cancer treatment, including novel antibody-drug conjugates, bispecific antibodies, and cytotoxic-sparing regimens for hormone receptor+ (HR+)/HER2+ disease, are creating exciting new options for patients.

Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.

Panelists discuss how they manage adverse effects of tucatinib-based therapy, particularly focusing on diarrhea and palmar-plantar erythrodysesthesia from capecitabine, with practical dosing strategies to improve tolerability.

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.

Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to potentially prevent brain metastases.

Panelists discuss how National Comprehensive Cancer Network (NCCN) guidelines inform third-line treatment options for HER2-positive (HER2+) metastatic breast cancer, with particular focus on the HER2CLIMB regimen (tucatinib, capecitabine, and trastuzumab) for patients with brain metastases.

Panelists discuss how fourth-line treatment options include margetuximab (which interacts better with the immune system), neratinib-capecitabine (an irreversible pan-HER inhibitor), and antibody-drug conjugates (ADCs) with different payloads, though toxicity profiles must be considered.

Panelists discuss how third-line treatment options after T-DXd progression include T-DM1 and the HER2CLIMB regimen (tucatinib-capecitabine-trastuzumab), with consideration of brain metastases as a key factor in treatment selection.

Panelists discuss how they would approach multiple brain metastases at initial metastatic diagnosis, debating the use of stereotactic radiosurgery vs systemic therapy with agents that cross the blood-brain barrier.

Panelists discuss how they approach the case of a 47-year-old marketing executive with initially low-risk HER2-positive (HER2+) breast cancer who developed brain, liver, lung, and bone metastases shortly after completing adjuvant therapy.

Panelists discuss how the treatment landscape for early HER2-positive metastatic breast cancer has evolved, with taxane-pertuzumab-trastuzumab as first-line standard of care and T-DXd supplanting T-DM1 as the preferred second-line treatment.

Panelists discuss how different gonadotropin-releasing hormone (GnRH) agonists like leuprolide and goserelin are equally efficacious for ovarian function suppression but differ in administration methods, needle size, and patient comfort.

Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtecan’s (T-DXd) efficacy in patients with brain metastases.

Panelists discuss how they manage adverse effects of trastuzumab deruxtecan (T-DXd), particularly focusing on nausea, fatigue, and the critical monitoring needed for interstitial lung disease (ILD), with recommendations for prophylactic antiemetics and frequent imaging.

Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and the impressive results from the PATINA trial adding CDK4/6 inhibitors to maintenance therapy.

Panelists discuss how a 52-year-old elementary school teacher diagnosed with HER2-positive (HER2+) breast cancer achieved pathologic complete response with neoadjuvant therapy but experienced metastasis 18 months after completing treatment, requiring first-line metastatic therapy.

Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

A panel of experts offer future perspectives in HR+ breast cancer.

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

A panel of experts discuss navigating 2L treatment strategies.

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.